Ionis Pharmaceuticals (IONS) vs Rhythm Pharmaceuticals (RYTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Rhythm Pharmaceuticals (RYTM) has outperformed Ionis Pharmaceuticals (IONS) over the past year, losing 11.4% versus a loss of 38.1%. Over five years, RYTM leads with a +682.1% price change compared with +23.4% for IONS. Ionis Pharmaceuticals is the larger company by market cap ($7.20 billion vs $6.17 billion), about 1.2 times the size, while Rhythm Pharmaceuticals is growing revenue faster (+45.8% vs +33.8%).
Ionis Pharmaceuticals converts more of its revenue into profit, with a net margin of -40.4% versus -103.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IONS | RYTM |
|---|---|---|
| Share price | $43.30 | $89.64 |
| Market cap | $7.20B | $6.17B |
| 1-day change | -1.95% | +1.35% |
| YTD return | -45.27% | -17.37% |
| 1-year return | -38.11% | -11.40% |
| 5-year return | +23.36% | +682.05% |
| EPS (TTM) | $-3.48 | $-3.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $943.71M | $189.76M |
| Revenue growth (YoY) | +33.83% | +45.83% |
| Net income (latest FY) | $-381.39M | $-196.54M |
| Gross margin | 98.31% | 89.73% |
| Operating margin | -40.45% | -101.19% |
| Net margin | -40.41% | -103.57% |
| 52-week high | $86.74 | $122.20 |
| 52-week low | $42.63 | $74.50 |
| Distance from 52-week high | -50.08% | -26.64% |
| Analyst consensus | buy | none |
| Avg. price target upside | +93.16% | +54.61% |
| Average volume | 3.51M | 649.06K |
| Shares outstanding | 166.18M | 68.85M |
| Employees | 1,480 | 414 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RYTM has outperformed IONS by 26.7 percentage points over the past year.
- Ionis Pharmaceuticals is more profitable, keeping -40.4 cents of every revenue dollar as net income versus -103.6 cents for Rhythm Pharmaceuticals.
- Rhythm Pharmaceuticals grew revenue faster in its latest fiscal year (+45.83% vs +33.83%).
About Ionis Pharmaceuticals
IONS stock →Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).
Health Care · Biotechnology: Pharmaceutical Preparations · 1,480 employees
About Rhythm Pharmaceuticals
RYTM stock →Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 414 employees
IONS vs RYTM FAQ
Which is bigger, Ionis Pharmaceuticals or Rhythm Pharmaceuticals?
Ionis Pharmaceuticals (IONS) is larger, with a market capitalization of $7.20B compared with $6.17B for Rhythm Pharmaceuticals (RYTM).
Which stock has performed better over the past year, IONS or RYTM?
RYTM returned -11.40% over the past 12 months, compared with -38.11% for IONS (price return, excluding dividends). Past performance does not predict future results.
Are Ionis Pharmaceuticals and Rhythm Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.